Skip to main content

Table 1 Patient characteristics at baseline

From: Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Characteristics

Patients (N = 205)

Median age (range), years

70 (44–91)

Gender: male / female

170 / 35

ECOG PS score: 0 / 1 / 2 / 3 / 4

49 / 120 / 29 / 6 / 1

Stage: II / III / IV recurrence

3 / 34 / 130 / 38

Histological types: ADC / SCC / NSCLC-NOS / other

123 / 54 / 22 / 6a

EGFR mutation: positive / negative / unknown

6b / 171 / 28

Smoking history: ever / never / unknown

182 / 19 / 4

PD-L1: 50–89% / 90–100%

138 / 67

Steroid use: yes / no

13 / 192

Best response: CR / PR / SD / PD

3 / 105 / 45 / 52

  1. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status, ADC adenocarcinoma, SCC squamous cell carcinoma; NSCLC-NOS non-small cell carcinoma -not otherwise specified, EGFR, epidermal growth factor receptor, PD-L1 programmed cell death ligand 1, CR complete response, PR partial response, SD stable disease, PD progressive disease, Ex19del exon 19 deletion
  2. apleomorphic carcinoma: four cases; spindle cell carcinoma: one case; large cell carcinoma: one case
  3. bEx19del: two cases; Ex19del + T790 M: one case; G719A: two cases; G719C: one case